Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Nanobiotix And HealthCare Royalty Ink 71M Non-Dilutive Financing Agreement To Support JNJ-1900 (NBTXR3) Development And Long-Term Growth

Author: Benzinga Newsdesk | October 31, 2025 02:18am

$71 million in funding would extend Nanobiotix cash visibility into early 2028
Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancer
Financing establishes financial foundation toward self-sustainability and the advancement of next wave nanotherapeutic platforms for long-term growth
HealthCare Royalty (HCRx) will receive a capped portion of milestones and royalties on sales of JNJ-1900 (NBTXR3) payable to Nanobiotix under its global licensing agreement

Posted In: KKR NBTX